MedTrace Logo

China Endeavor Registry: A Registry With The Endeavor Zotarolimus Eluting Coronary Stent in China

NCT00793312 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2210

Last updated 2012-10-17

No results posted yet for this study

Summary

The primary objective is to document the acute and mid-term safety and overall clinical performance of the Endeavor(TM) Zotarolimus Eluting Coronary stent system in a "real world" Chinese patient population requiring stent implantation.

To assess the event rate in patient subgroups with specific clinical indications and/or vessel or lesion characteristics.

Conditions

Sponsors & Collaborators

  • Medtronic Cardiovascular Asia Pacific

    collaborator INDUSTRY

  • Medtronic Vascular

    lead INDUSTRY

Principal Investigators

  • Jiyan Chen, Professor · Guangdong Provincial People's Hospital

  • Yaling Han, Professor · Shenyang North Hospital

  • Yong Huo, Professor · Peking University First Hospital

  • Weimin Wang, Professor · Beijing People's Hospital

  • Bo Xu, Director · Fu Wai Hospital, Beijing, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-09-30
Completion
2010-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00793312 on ClinicalTrials.gov